Ruth Beran talks with Iatia boss Charles Laycock about the importance of being smart and flexible in designing a good biotech business model.

Microscopy company Iatia (ASX:IAT) will achieve its first positive operating cash flow quarter for the period ended June 30.

Phase imaging enhancement specialist Iatia (ASX:IAT) is showing the early stages of a turnaround following the signing of two deals within the last month.

Acrux [ASX: ACR] has announced positive results for a Phase 1 proof-of-concept, pharmacokinetic study of its contraceptive spray Nesterone MDTS.

Biotech companies which have failed to raise enough capital to see them through to the next funding cycle might expire as a funding drought sets in, and blame "shocking" market conditions for forcing them to abandon or change their plans.

The Victoria Prize was awarded today to Melbourne University physicist Prof Keith Nugent for his work on phase imaging and X-ray optics.

Genetic Technologies' (ASX: GTG) increased loss, as reported in the company's half-year results last week, was in part due to changes in accounting required for the company's upcoming listing on the US Nasdaq market through the level 2 ADR program, executive chairman Dr Mervyn Jacobson said today.

Microscopy company Iatia (ASX:IAT) released its annual results last Friday with a brutally honest assessment of their performance over the 2002-2003 year.

Microscopy company Iatia has received a 'please explain' from the Australian Stock Exchange after its fourth quarter results showed the company had a net negative operating cash flow for the quarter of AUD$671,000 and $296,000 cash remaining.

Melbourne-based imaging technology developer Iatia is positive about the prospects of the company despite low cash reserves, CEO Brian Powell said today.

Iatia's QPe phase imaging technology proved popular at the recent International Congress on Electron Microscopy in Durban, South Africa, according to CEO Brian Powell.